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Effect of intensive therapy on the development and progression
of diabetic nephropathy in the Diabetes Control and
Complications Trial
THE DIABETES CONTROL AND COMPLICATIONS (DCCT) RESEARCH GROUP1
Effect of intensive therapy on the development and progression of
diabetic nephropathy in the Diabetes Control and Complications Trial.
The Diabetes Control and Complications Trial (DCCT) has demonstrated
that intensive diabetes treatment delays the onset and slows the progres-
sion of retinopathy, nephropathy, and neuropathy in patients with IDDM.
A detailed description of the effects of this treatment on diabetic
nephropathy is presented here. In the primaiy prevention cohort, inten-
sive treatment reduced the mean adjusted risk of the cumulative incidence
of microalbuminuria (28 j.rmin) by 34% (95% CI 2, 56%; P = 0.04).
Furthermore, intensive treatment decreased the albumin excretion rate
(AER) by 15% after the first year of therapy (6.5 vs. 7.7 jrg/min, P <
0.001). Thereafter the rates of change for AER within each treatment
group were no different from zero, retaining a constant difference in AER
between groups in the trial. In the secondaiy intervention cohort with
baseline AER <28 g/min, intensive therapy reduced the mean adjusted
risk of microalbuminuria (28 xWmin) by 43% (95% CI 21, 58%; P <
0.0001); the risk of a more advanced level of microalbuminuria (70jg/min) by 56% (95% CI 26, 74%; P = 0.002); and the risk of clinical
albuminuria (208 .rgImin) by 56% (95% CI 18, 76%; P < 0.01). In the
secondary intervention cohort, values for AER at year 1 were identical at
9 .rg/min, but the 6.5% change per year in the conventional group greatly
exceeded the rate of change of —0.3% in the intensive group (P < 0.001).
Among the 73 secondary cohort subjects with AER levels 28 rWmin but
139 JLg/min at baseline, the reduction of progression to clinical albumin-
uria with intensive therapy was not statistically significant. The longitudi-
nal treatment effect of conventional versus intensive therapy (11.0% vs.
2.5% per year, respectively, P = 0.087) was similar in magnitude to that
among patients with AER <28 rg/min at baseline. For the primary,
secondary and combined cohorts, there were no significant differences in
the rates of change in creatinine clearance (Car) between treatment
groups during the study. Only seven subjects in the entire study (2
intensive, 5 conventional) developed urinary AER 208 g/min coupled
with a Cr <70 ml/min/1.73 m2. Neither the rate of change of blood
pressure nor the appearance of hypertension (BP >140/90 mm Hg)
differed significantly between treatment groups in the primary, secondary
or combined cohorts. The beneficial effect of intensive therapy on the
development of microalbuminuria was consistent in subgroups defined by
baseline variables including age, diabetes duration, baseline HbAIC, level
of retinopathy, neuropathy, and the presence or absence of hyperfiltration
(Ccr < 130 or 130 ml/min/1.73 m2). Even after adjustment for preg-
nancy, female subjects nearly demonstrated (P = 0.06) a smaller treatment
effect than male subjects. In summary, intensive therapy reduced the
cumulative incidence and overall risk for the development of microalbu-
minuria and clinical albuminuria in both the primary prevention and
secondary intervention DCCT cohorts. The consistent beneficial effect of
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intensive therapy may prevent the onset and will at least delay progression
of nephropathy; it may also delay or prevent the development of advanced
renal disease in IDDM patients.
Diabetic nephropathy accounts for 25 to 30% of the patients
with end-stage renal disease who require dialysis [1—3] and it has
been estimated that 30 to 40% of patients with insulin dependent
diabetes mellitus (IDDM) will eventually develop end stage renal
disease [4—6]. A number of factors may interplay in the patho-
genesis of diabetic nephropathy, including metabolic, hemody-
namic and, as yet poorly defined genetic and/or environmental
determinants.
The Diabetes Control and Complications Trial (DCCT) was a
29 center, randomized clinical trial that compared the effects of
intensive diabetes treatment, designed to achieve glucose levels as
close to normal as possible, with conventional diabetes treatment
on the development and progression of the long-term complica-
tions of IDDM [7]. The DCCT studied two cohorts of IDDM
patients to answer two separate but related questions: (1.) Would
intensive treatment prevent or delay the development of compli-
cations in subjects who had no complications at baseline (primary
prevention trial); and (2.) Would intensive treatment prevent or
slow progression of complications in subjects who had early
complications at baseline (secondary intervention trial)? We have
previously reported that intensive diabetes therapy delays the
onset and slows the progression of retinopathy and delays the
development of microalbuminuria (28 .tg/min) in both cohorts
and the development of overt nephropathy (albuminuria >208
.tg/min) in the secondary intervention cohort [8]. We now present
detailed analyses of changes in renal function in the primary
prevention and secondary intervention cohorts, comparing the
results in the subjects receiving intensive therapy with those
receiving conventional diabetes treatment. These analyses in-
clude: [1] life-table analyses which summarize the cumulative
incidences of events over time; [2] comparison of treatment
groups at specific points in time (point prevalence); and [3]
longitudinal analyses of the rates of changes (slopes) of renal
function in individuals over time.
Methods
Patients
Detailed descriptions of the eligibility criteria and randomiza-
tion procedures for subjects entering the DCCT as well as their
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baseline renal function have been published [7—9]. All subjects
were 13 to 39 years of age and had a duration of IDDM of ito 15
years at randomization. They were free of advanced micro- or
macrovascular complications of diabetes, had normal glomerular
filtration rates evidenced by a serum creatinine <1.2 mg/dl and/or
creatinine clearance (Car) >100 ml/min/1.73 m2 and were nor-
motensive (BP < 140/90 mm Hg). They had no other significant
medical or psychiatric disorders that might complicate their care
or limit their participation in the study, were free of neuropathy of
sufficient magnitude to require symptomatic treatment, and had
calculated LDL cholesterol levels <190 mg/dl. LDL cholesterol
was calculated with the Friedewald equation with very-low-density
lipoprotein cholesterol (VLDL) concentration assumed to be
20% of triglyceride concentration [10]. Subjects with a history of
heavy alcohol consumption within the five years prior to entry or
regular use of analgesics were also excluded.
The primary prevention cohort consisted of 726 subjects who
fulfilled the following additional selection characteristics at entry:
duration of IDDM one to five years, stimulated serum C-peptide
levels <0.5 pmol/ml, no retinopathy visible on stereo fundus
photography, and a urinary albumin excretion rate (AER) <28
ig/min. The value of 28 /hg/min for AER lies in the middle of the
range of values cited as being "predictive" of clinical nephropathy
[11—14]. At entry, mean duration of diabetes was 2.6 1.4 years,
mean age was 26 7 years, mean Cr was 127 29 ml/min/1.73
m2 and median urinary AER was 8 6 g/min (Table 1 and Fig.
1) [9].
The secondary intervention cohort consisted of 715 subjects
who fulfilled the following additional selection characteristics at
entry into the study: duration of IDDM 1 to 15 years, stimulated
C-peptide levels <0.2 pmol/liter for subjects with five years or
more duration of IDDM, minimal to moderate retinopathy (at
least 1 microaneurysm in one eye but <P2 by modified Airlie
House criteria [15] visible on stereo fundus photography, and
urinary AER levels <139 g/min. At entry, duration of diabetes
was 8.7 3.7 years, mean age 27 7 years, mean Cr 129 31
ml/min/1.73 m2 and median urinary AER 9.7 12.5 jig/mm
(Table 1 and Fig. 1). Seventy-three secondary intervention sub-
jects had urinary AER 28 j.tg/min [9].
Baseline characteristics (Table 1 and Fig. 1) did not differ
between the treatment groups within each cohort with respect to
the variables listed. Data used for the subgroup analyses were
collected at baseline and have been described in detail previously
[8,9].
Due to staggered entry of subjects during 1983 to 1989, not all
subjects had the same number of measurements by study end. The
278 subjects who entered during the feasibility segment of the trial
in 1983 to 1984 provided the longest period of observation of up
to nine years. The majority of the additional 1163 patients
recruited for the full scale trial were followed for at least four
years. The principal analyses employed all 1441 patients entered
into the trial, feasibility and full scale phases combined, Addi-
tional analyses were performed using only those 278 patients
entered during the feasibility phase, 268 of whom were followed
for nine years.
Assessment of renal Jimction and blood pressure
Details regarding blood pressure measurement, the methods of
urine collection and blood collection and measurement of creat-
mine and albumin and quality control procedures for these
N
Demographics
Age years
Gender (% female)
Race (% Caucasian)
IDDM
Duration years
HbAlc %
Clinical and
biochemical features
Body mass index
kg/rn2
Male
Female
Cholesterol
mgldl, serum
Triglycerides rng/dl,
serum
HDL-cholesterol
mg/dI, serum
LDL-cholesterol
mg/dl, serum
Smoking history %
History of kidney
infection %
Dietary protein
g/daylkg
Familial
Family history of
diabetes
Family history of
hypertension %
Family history of
kidney disease
Family history of
diabetic kidney
disease
Data are means SD unless otherwise indicated.
methods have been described in detail previously [9]. Briefly,
urine collection began after the subjects had breakfast and their
morning dose of insulin. If a subject had a hypoglycemic reaction
the collection was delayed so that the subject was without
symptoms for at least one hour. Subjects were asked to avoid
strenuous exercise the day previous to the test. Urine collections
were obtained with the subjects resting and in a sitting position
and abstaining from caffeinated beverages. Subjects were asked to
drink 250 ml of water every half hour during the four hours. The
carefully timed specimens were collected on ice, mixed, their total
volume measured and aliquots frozen for later assay. Clinic and
laboratory quality control were continuously monitored through-
out the study by having the laboratory analyze split aliquots from
single specimens. For measurements of urine albumin and creat-
mine and serum creatinine, the respective coefficients of variation
were 6.6, 4.0 and 4.0%, and the respective coefficients of reliability
were 98, 99 and 86%.
Clinic personnel were masked to the results of renal function
measurements. However, if a patient developed a serum creati-
nine >2.0 mg/dl, the patient and clinic staff were unmasked to this
finding so that additional diagnostic tests could be performed or
therapeutic measures initiated, if indicated. In the absence of
Table 1. Selected baseline characteristics
Primary prevention
Conventional Intensive
378
26 8
46
96
348
27 7
51
96
Secondary intervention
Conventional Intensive
352 363
27±7 27±7
46 47
97 97
2.6 1.4 2.6 1.4 8.6 3.7 8.9 3.8
8.8 1.7 8.8 1.6 8.9 1.5 9.0 1.5
24 323 3
173 35
77 57
51 13
23 323 3
176 33
75 41
52 13
24 324 3
179 32
87 44
49 11
23 324 3
178 33
86 45
49 12
112 29
35
21
1.6 0.6
106 30 109 29 112 28
36 36 36
18 18 17
1.7 0.6 1.6 0.5 1.5 0.5
15 14 14 14
55 59 57 54
11 11 8 8
3 2 2 2
C)I
E
E
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clinical data or renal biopsy findings to the contrary, we assumed
that the underlying kidney disease was diabetic nephropathy.
There was only one case documented to have nephropathy from a
cause other than diabetes during the study.
An increase in urinary AER may be the earliest manifestation
or a marker of diabetic nephropathy [11—14]. Therefore, we
compared this parameter measured annually between treatment
groups in the two cohorts. Urine collections were performed for
four hours rather than 24 hours and results for AER will be
expressed in terms of j.tg/min rather than mg/24 hours, as previ-
ously reported [8].
Beginning five years after initiation of the DCCT, 125j
iothalamate clearance studies were performed on all new patients
at entry as an additional measurement of GFR. These measure-
ments were performed in most subjects after three years in the
study and at study end. The details of the methodology and
coefficients of variation have been described previously [16]. All
iothalamate and creatinine clearances were adjusted for body
surface area at baseline to avoid introducing changes in renal
function owing to differences in weight gain that occurred during
the trial between the intensive and conventional treatment groups
[17].
Statistical analysis
All outcomes were analyzed on the basis of original treatment
assignment. Major events of interest were defined prior to study
end while the study group was still masked to study results. These
events were the following: albuminuria >28 jxg/min (40 mg/24 hr),
>70 jxg/min (100 mg/24 hr), and >208 xgImin (300 mg124 hr).
The development of renal insufficiency was defined as the obser-
vation of an AER >208 jxg/min and a Cr <70 ml/min/1.73 m2 on
the annual evaluation. Hypertension was defined as a sitting
systolic blood pressure >140 mm Hg or diastolic blood pressure
>90 mm Hg on two consecutive readings one month apart. Event
rates are presented as number per 100 patient years based on the
ratio of the observed number of patients experiencing the event
(cases) to the total patient years of exposure (at risk). The
lifetable method was used to estimate the cumulative incidence of
events [18] with adjustments for periodically timed assessments
[19].
The average relative risk comparing the two treatment groups
within each of the primary and secondary cohorts over the
complete period of observation was estimated by a proportional
hazards (PH) regression model [18], with adjustment for the
numerical baseline value. The Wald test from the PH model was
used to test the difference between cumulative incidence curves.
The adjusted percentage reduction in risk for intensive therapy
versus conventional therapy was calculated from the average
adjusted relative risk (RR) of intensive versus conventional
treatment as (1 — RR) x 100%. The relative risk in the combined
cohorts was estimated with stratification by primary and second-
ary cohorts.
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Fig. 1. Baseline distribution of (A) albumin
excretion rate (AER), (B) creatinine clearance,
and (C) systolic and (D) diastolic blood pressures
shown for intensive (I) and conventional (C)
treatment subjects in the primaty and seconda,y
cohorts. For each parameter the median is
shown by an X with the 25th and 75th
percentiles shown by the boxes and the 5th and
95th percentiles shown by the bars.
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The Wilcoxon rank sum test was used to compare the treatment
groups with respect to the distributions of ordinal or numerical
variables, and the contingency test for categorical variables
[20]. For the analysis of repeated measurements over time of an
ordinal or a numerical variable, the multivariate Wilcoxon anal-
ysis [21] was employed in conjunction with an overall test of
differences between groups using weights proportional to the total
sample size at each annual evaluation [22]. The repeated mea-
sures analysis of AER and CCr employed a covariance adjustment
for the baseline values on the log scale. Because iothalamate
clearance was not measured at baseline in the majority of patients,
analyses of iothalamate clearance did not employ a covariance
adjustment for baseline values.
The distributions of AER at baseline were strongly positively
skewed, demonstrated by means that were somewhat larger than
their respective medians. Thus, the natural log (In) transformation
was employed to improve the distributions of these measures.
However, the mean, standard deviation (so) and percentiles of the
ln(measures), are not as readily interpretable as those in the
original units of measurement. Thus, the exponential function of
the mean on the In scale was used to convert the mean of the
ln(measures) back to the original units of measurement. This
yields the geometric mean which is an estimate of the median
under a In-normal distribution. In general, these geometric means
corresponded favorably to the medians of the original nontrans-
formed data (Table 4).
Random effects models for the analysis of longitudinal data
(so-called growth curve models) were employed to describe the
rates of change of renal function measures (albuminuria, creati-
nine clearance and blood pressure) over time [23, 24]. The basic
model for each patient was of the form: log (yt) = a + 13 (t — 1),
where t represents the year of evaluation. Thus the intercept (a)
reflects the fitted value at year 1. Since the natural log of y was
employed, the slope 13 * 100 is approximately the relative (%)
change per year. These analyses employed the baseline level of
the measure as a covariate in the model because eligibility
restrictions on these measures would lead to biased estimates if
the baseline values were included in the slope calculations [25].
In these models, the treatment effect was partitioned into two
components: the acute effect of treatment and the long-term
effect. The acute effect of intensive versus conventional treatment
is reflected by a difference between groups at the first year of
follow-up. Time (t) is re-scaled as t — 1 so that t — 1 0
corresponds to year 1 of follow-up. Then the average intercept for
the subjects in a treatment group gives an estimate of the
geometric mean at year 1 of follow-up. The difference between
these average group intercepts, or the ratio of the geometric
means, provides an estimate of the acute treatment effect. For
each subject a regression model is fit to all values from year 1 and
later, with subjects having differing numbers of follow-up mea-
sures based on their length of participation in the trial. Then the
difference between groups in the average slopes (relative %
change per year) reflects the differences in trends beyond the first
years of follow-up.
The Appendix describes in greater detail the models employed
and the precise estimates of the model coefficients and variance
components for the analyses of AER. This detailed information is
provided to assist others who may wish to conduct similar analyses
of data from other trials, or more importantly, to use the
parameter estimates of the coefficients and variance components
for the planning of future clinical trials of pharmacologic or
therapeutic interventions in the treatment of diabetic nephropa-
thy. The analyses were performed using the program 5V of the
BMDP [26].
For the analyses within a cohort (that is, the primary or the
secondary cohort), the model included the baseline value as a
covariate, treatment group as a group effect, and the intercept and
time (slope) as random effects, and a group by time interaction.
For subgroup analyses (such as by gender), separate analyses were
performed within each subgroup (for example, for males and for
females). An additional model was employed with the subgroup-
ing covariate (such as gender) and its interactions with the above
factors added to the model so as to provide a test of the covariate
by treatment interaction (homogeneity).
Results are presented as mean SD unless otherwise noted. All
results nominally significant at P < 0.05 are indicated.
Results
There were no significant differences in baseline data between
the treatment groups in either the primary prevention or the
secondary intervention cohorts (Table 1). The distributions of
AER, Ccr, and systolic and diastolic blood pressures at baseline
are given in Figure 1. Baseline iothalamate clearance performed
in 476 subjects was 128 (± 20) ml/min/1.73 m2 and did not differ
among the randomized treatment groups.
Extent of follow-up and adherence to assigned treatment
The mean duration of follow-up for the entire cohort of 1441
subjects was six and one-half years with a range of three to nine
years. Two patients did not undergo any follow-up renal assess-
ments: one intensively treated patient in the primary cohort, and
one conventionally-treated patient in the secondary cohort. More
than 2000 patient years were accrued in each treatment group for
each cohort for a total of approximately 9300 patient years of
observation. In the various life-table analyses, however, the total
patient-years "at risk" are somewhat less than the total years of
follow-up because exposure time is calculated up to the time of
the event (or end of the study). Follow-up in the study was
virtually complete. End of study data were collected on 1422
subjects, 99% of the total cohort. The reasons for subjects failing
to complete the study included 11 who died and 8 drop-outs.
The subjects' adherence to their randomly assigned treatment
was also high. Overall, subjects randomly assigned to intensive
treatment spent more than 98% of their time using intensive
therapy and subjects assigned to conventional treatment spent
more than 97% of time during the study using conventional
therapy. This included 95 women who deviated from their as-
signed conventional treatment according to protocol in prepara-
tion for and during pregnancy. Conventional therapy was resumed
when the pregnancy ended in all women assigned to conventional
therapy.
At baseline, mean HbAIC levels were similar in both treatment
groups (Table 1). By three months after randomization, mean
HbAIC was approximately 2% lower in the intensive treatment
group than the conventional treatment group and this difference
was maintained throughout the study, (7.2 vs. 9.1%, P < 0.001).
Urinary albumin excretion
Cumulative incidence analyses. We compared the intensively
and conventionally treated subjects for the development of vari-
ous levels of AER. Table 2 shows the incidence rates and the risk
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Table 2. Summaiy of absolute rates for development of levels of AER and percentage risk reduction with intensive therapy
Primary preventio % Secondary intervention
Combined cohortsb
%
Reduction (95% CI)Cony Tnt Reduction (95% CI) Cony Tnt Reduction (95% CI)
A. Patients with AER < 28 J.rg/min at baseline'
Albuminuria  28 g/min (40 mg124 hrs)
# Cases 67 41 99 69
Rate/100 py 3.4 2.2 34 (2, 56) 5.7 3.6 43 (21, 58)" 39 (21, 52)"
Cum % @ 9y 27.3 16.0 42.1 26.2
Sustainede albuminuria  28 tg/min
# Cases 18 7 49 23
Rate/100 py 0.9 0.4 56 (—5, 82) 2.53 1.1 61 (36, 77)" 60 (37, 74)"
Cum % @ 9y 6.9 2.7 18.6 7.4
Albuminuria  70 jg/min (100 mg/24 hrs)
# Cases 18 10 43 22
Rate/100 py 0.9 0.5 39 (—34, 72) 2.2 1.03 56 (26, 74)" 51 (24, 68)"
Cum % @ 9y 7.0 3.3 20.2 10.0
Sustainede albuminuria  70 rg/min
#Cases 5 2 23 9
Rate/100 py 0.2 0.10 54 (—136,91) 1.1 0.4 67 (28, 84)" 65 (29, 83)"
Cum % @ 9y 7.0 3.3 8.3 3.1
B. All patientsd
Albuminuria  208 g/min (300 mg124 hrs)
#Cases 6 3 31 15
Rate/100 py 0.3 0.2 44 (—124, 86) 1.4 0.6 56 (18, 76)" 54 (19,74)"
Cum % @ 9y 2.3 2.6 11.3 5.2
Sustainede albuminuria  208 Wmin
# Cases 22 11
Rate/100 py1 1.0 0.5 56 (8, 79)" 51 (2, 75)"
Cum%@9y 7.2 3.2
a Percent reduction: percentage risk reduction of intensive compared with conventional treatment calculated from a proportional hazards model
adjusted for baseline AER values
bStratified by primary prevention vs. secondary intervention
Patients with AER > 28 .tgImin at baseline excluded, including one intensive-treated patient in the primary cohort.
Primary Prevention Cohort (Conventional N = 378; pt years = 2192; Intensive N = 346; pt years = 2010)
Secondary Intervention Cohort (Conventional N = 316; pt years = 2367; Intensive N = 325; Pt years = 2468)
Total patient years of follow-up of AER assessments (0—9 yr per patient). Patient years at risk slightly less in each analysis depending on the number
and timing of events.
dTwo patients excluded who did not complete at least one annual evaluation.
Primary Prevention Cohort (Conventional N = 378; pt years = 2192; Intensive N = 347; pt years = 2010)
Secondary Intervention Cohort (Conventional N = 351; pt years = 2367; Intensive N = 363; pt years 2468)eEvent observed at two successive annual evaluations.
Number of cases too small (< 5) to allow meaningful analysis.
gp < 0.05, two-tailed, hp < 0.01, two tailed
reduction with intensive therapy. Table 3 shows the incidence
rates partitioned over time. Figures 2 to 4 show the cumulative
incidence curves. In the following sections the results of these
analyses are described.
Microalbuminuria 28 pg/mm
Primary prevention cohort. Of the 346 intensively treated sub-
jects, 41 developed microalbuminuria during 1876 person-years at
risk, for an overall hazard rate of 2.2 per 100 patient-years at risk.
By lifetable analysis, the cumulative incidence of microalbumin-
uria after nine years was estimated to be 16% (Table 2). Of the
378 conventional therapy subjects, 67 developed microalbumin-
uria during 1987 person-years at risk, for an overall hazard rate of
3.4 per 100 patient-years at risk and a nine-year estimated
cumulative incidence of 27%. The difference in the cumulative
incidence curves (Fig. 2A) between the two treatment groups was
significant (P = 0.04). The average relative risk (conventional vs.
intensive), adjusted for baseline AER levels, was 1.51 with a 95%
confidence interval (CI) of 1.02, 2.25. This corresponds to a 34%
reduction in risk with intensive treatment (95% CI: 2,56).
Whereas the rate of cases developing microalbuminuria in the
conventionally treated group increased modestly over time, the
converse was seen in the intensively treated group, resulting in a
rather striking increase in the relative risk (Conventional vs
Intensive) over time (Table 3).
Secondary intervention cohort. Sixty-nine of the 325 intensively
treated subject with baseline AER <28 pg/mm developed mi-
croalbuminuria during 1940 person-years at risk, for an overall
hazard rate of 3.6 per 100 patient-years at risk. The cumulative
incidence after nine years was 26%. Of the 316 conventional
therapy subjects with baseline AER <28 .tg/min, 99 developed
microalbuminuria during 1736 person-years at risk, for an overall
hazard rate of 5.7 per 100 patient-years at risk. The nine-year
cumulative incidence was 42%. As in the primary prevention
cohort, the difference in the cumulative incidence curves (Fig. 2b)
between the two treatment groups was significant (P < 0.001).
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Table 3. Incidence of nephropathy events for different time periods
Years of
Conventional (C) Intensiye (I) Relative risk: C vs. I
Per Per
Event study time N Cases yrs Rate N Cases yrs Rate Unadjusted Adjusted
AER > 28 g/min in 0—1 378 10 378 2.65 346 11 346 3.18 0.83
primary cohort with 2—3 367 26 719 3.62 335 18 659 2.73 1.32
baseline AER < 28 jtg/min 4—5
6—9
339
143
17
14
597
293
2.85
4.78
314
148
7
5
548
323
1.28
1.55
2.23
3.09
0—9 378 67 1987 3.37 346 41 1876 2.19 1.56 (1.05, 2.32)b 1.51 (1.02, 2.25)
AER > 28 ig/min in 0—1 316 19 316 6.01 325 18 325 5.54 1.09
secondary cohort with 2—3 297 39 572 6.82 307 24 597 4.02 1.70
baseline AER < 28 jgfmin 4—5
6—9
258
167
26
15
500
348
5.20
4.31
281
204
14
13
555
463
2.52
2.81
2.06
1.54
0—9 316 99 1736 5.70 325 69 1940 3.56 1.62 (1.18, 2.22) 1.74 (1.26, 2.39)
AER > 208 jgImin in 0—1 729 2 729 0.27 710 4 710 0.58 0.49
all patients 2—3
4—S
6—9
726
714
417
8
14
13
1448
1336
938
0.55
1.05
1.39
705
694
437
5
4
5
1404
1301
1002
0.36
0.31
0.50
1.55
3.41
2.78
0—9 729 37 4451 0.83 710 18 4417 0.41 2.07 (1.17, 3.63) 2.18 (1.23, 3.85)
Rate is cases per 100 person-years.
aWithin Primary and Secondary Cohorts, adjusted for log of AER at baseline as a continuous variable. In the analysis of all patients also adjusted
for primary and secondary cohort status.
"Relative risk (95% confidence interval)
The adjusted relative risk (conventional vs. intensive) was 1.74
(95% CI: 1.26, 2.39), giving a mean reduction in absolute risk with
intensive therapy of 43% (95% CI 21, 58%). In the secondary
cohort, the increase in the relative risk with time was less
pronounced than in the primary intervention cohort (Table 3).
Combined cohorts. Of the 671 intensively treated subjects with
baseline AER <28 gImin, 110 developed microalbuminuria. For
the 694 conventionally treated subjects with baseline AER <28
g/min, 166 developed microalbuminuria. The difference in the
cumulative incidence curves between the two treatment groups in
the total study was significant (P < 0.001). The adjusted relative
risk (conventional vs. intensive) was 1.63 (95% CI: 1.27, 2.08),
giving a reduction in absolute risk with intensive therapy of 39%
(95% CI: 21, 52) (Table 2).
Microalbuminuria 7O p.g/min
We also explored the risk of developing more advanced levels
of microalbuminuria among those who had baseline AER <28
g/min at baseline.
Primary prevention cohort. Ten intensively treated subjects
developed an AER >70 g/min (Fig. 3A). This resulted in a
cumulative incidence after nine years of 3.3% and an overall
hazard rate of 0.5 per 100 patient-years at risk (Table 2). Eighteen
conventional therapy subjects developed AER >70 Wmin (Fig.
3A). The cumulative incidence and overall hazard rate were 7.0%
and 0.9 per 100 patient years, respectively.
Secondary intervention cohort. Twenty-two intensively treated
subjects with baseline AER <28 g/min developed an AER >70
gImin (Fig. 3B). This resulted in a cumulative incidence of
10.0% after nine years and an overall hazard rate of 1.03 per 100
patient-years at risk. Forty-three conventional therapy subjects
developed an AER >70 g/min (Fig. 3B). The cumulative
incidence and overall hazard rate were 20.2% and 2.2 per 100
patient years respectively. The difference in the cumulative inci-
dence curves between the two treatment groups was significant at
P 0.002 (Fig. 3B). The adjusted relative risk (conventional vs.
intensive) was 2.28 (95% CI: 1.35, 3.85), giving a mean reduction
in absolute risk with intensive therapy of 56% (95% CI: 26, 74%)
(Table 2).
Combined cohorts. Of the 671 intensively treated subjects with
baseline AER <28 g/min, 32 developed an AER >70 Wmin.
Sixty-one of the 694 conventional treatment subjects with baseline
AER <28 gfmin developed an AER >70 gImin. The adjusted
relative risk (conventional vs. intensive) was 2.03 (95% CI: 1.32,
3.14), giving a mean reduction in absolute risk with intensive
therapy of 51% (95% CI: 24, 68, P < 0.001; Table 2).
Clinical albuminuria _>208 pg/mm
Primary prevention cohort. Only three intensively treated sub-
jects developed clinical albuminuria (cumulative incidence after 9
years of 2.6% and an overall hazard rate of 0.15 per 100
patient-years at risk; Table 2). Six conventional therapy subjects
developed clinical albuminuria. The cumulative incidence and
overall hazard rate were 2.3% and 0.28 per 100 patient years,
respectively. The cumulative incidence curves were not signifi-
cantly different.
Secondary intervention cohort. Fifteen of 363 intensively treated
subjects developed clinical albuminuria. This resulted in a cumu-
lative incidence after nine years of 5.2% and an overall hazard
rate of 0.62 per 100 patient-years at risk (Table 2). Of 357
conventional treatment subjects, 31 developed clinical albumin-
uria. The cumulative incidence and overall hazard rate were
11.3% and 1.36 per 100 patient years, respectively. The difference
in the cumulative incidence curves between the two treatment
groups was significant (P < 0.01; Fig. 4). The adjusted relative risk
(conventional vs. intensive) was 2.27 (95% CI: 1.21, 4.23), giving
a mean reduction in absolute risk with intensive therapy of 56%
(95% CI: 18, 76%; Table 2). As with microalbuminuria, this
relative risk was not constant over time in the study (Table 3).
Although numbers in each year were relatively small, there was a
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Fig. 2. Cumulative incidence of development of microalbuminuria (AER
>28 ig/min) in the intensive (diamonds) and conventional (U) treatment
groups. A. Primary prevention cohort (P = 0.04). B. Secondary interven-
tion cohort (among those with baseline AER <28 sg/min; P = 0.001).
tendency for a decrease in the rate of development of clinical
albuminuria in the intensively treated group in the secondary
intervention cohort, contrasting to an increase in the rate in the
conventionally treated group. This resulted in a trend toward an
increase in the relative risk over time.
Sustained microalbuminuria and clinical albuminuria
Subjects reaching the stipulated levels of AER (28, 70 and 208
g/min) on two successive annual evaluations were designated to
have sustained elevations of AER. The hazard rates, cumulative
percentages at nine years and risk reductions for these sustained
elevations are given in Table 2. Intensive therapy reduced the
average risk for development of sustained outcomes by 51 to 67%,
levels slightly greater than the less stringent single measurement
outcomes.
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Fig. 3. Cumulative incidence of development of AER >70 pg/mm) in the
intensive (diamonds) and conventional (U) treatment groups. A. Primary
prevention cohort (P = 0.219). B. Secondary intervention cohort (among
those with baseline AER <28 pg/mm; P = 0.002).
Point prevalence analyses
The variability of AER is well known and some subjects recover
from microalbuminuria or even clinical albuminuria. Unlike the
analysis of cumulative incidence, the analysis of prevalence re-
flects the status of a patient at a given visit regardless of the status
at other visits and incorporates the possibility of recovery. Figure
5 A and B show the point prevalence or the percent of subjects in
each of the categories, 28 to 70 iglmin, 70 to 208 tgImin, and
>208 gImin, at each annual follow-up visit in the primary
prevention and secondary intervention cohorts. In both cohorts,
the relatively steep increase in percent of conventional treatment
group patients with microalbuminuria or clinical albuminuria
contrasts with the more gradual increase in the intensive treat-
ment group. Formal tests of the overall difference between the
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Fig. 4. Cumulative incidence of development of clinical albuminuria AER
>208 pg/min) among all subjects in the intensive (diamonds) and conven-
tional (U) treatment groups in the secondaiy intervention cohort (P = 0.01).
Primary prevention cohort. Within the intensively-treated group,
the geometric mean (in- normal median) was stable over time
(Table 4). However, the upper quartile increased over time,
indicating increasing spread (and positive skewness) in the distri-
bution of the measures. Within the conventionally treated group,
both the mean and upper quartile increased with time.
The analysis of longitudinal changes in AER was divided into
the acute effects of intensive therapy (at one year of therapy) and
the long-term effects (after the first year). Using a growth curve
analysis in the primary prevention cohort on the in scale (see
Methods and detailed model described in the Appendix), the
difference in intercepts between treatment groups provides a
direct estimate of the ratio of the geometric means at year 1
(Table 5). The estimated ratio of 0.85 (significantly different from
1, P < 0.0001) indicated that the estimated geometric mean
(median) of AER after one year of treatment is 15% less among
intensively treated than conventionally treated subjects. The fitted
model also provides an estimate of the individual group geometric
means (medians) at year 1, and the group difference which is
estimated to be —1.14 .tg/min.
The long-term trend is reflected by the average slope of the
ln(AER) per year of follow-up beyond the first year. This is
equivalent to the average relative (or percent) change in AER per
year, estimated to be —1.31%/year in the intensive treatment
group and —0.52%/year in the conventional treatment group
(Table 5). The long-term effect of intensive versus conventional
treatment is the difference in mean slopes which is —0.79%/year
(P = 0.51). Thus, the AER in both treatment groups showed a
slight trend to decrease with time, but neither trend was signifi-
cantly different from zero (no change over time), or each other.
The overall difference between intensive versus conventional
treatment in the primary cohort, therefore, is reflected by the
acute effect of treatment at year 1 rather than a long-term effect
Year and treatment group
Fig. 5. Point prevalence of albuminuna at different levels [(U) 28—70,
(vertical striped box) 70—208, and (U) 208 igImin) over the course of the
study in the intensive (I) and conventional (C) treatment groups. A. Primary
prevention cohort. B. Secondary intervention cohort. Overall differences
between treatment groups were significant for primary and secondary
cohorts (P < 0.001).
on the slopes. A bivariate test of both temporal components of
this overall difference between intensive and conventional therapy
is highly significant (P < 0.0001; Table 5), principally due to the
acute effects of intensive treatment. An alternate explanation
would be that only a subset of patients benefit by intensive therapy
and the difference between treatment groups is diluted out when
the rate of AER in all patients is considered.
Even though the distributions of slopes in the two treatment
groups did not differ significantly (Fig. 6A), a large fraction of the
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two treatment groups over time were significant (P < 0.001 in
each of the primary prevention and secondary intervention co-
horts).
Analyses of rates of change of AER
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Table 4. Urinary albumin excretion rate (g/min) over time presented
as geometric mean and estimated quartiles from a in-normal
distribution
Intensive Conventional
Geometric Geometric
Time in years N mean 25% 75% N mean 25% 75%
A. Primary cohort
0 348 6.6 4.3 10.2 378 6.7 4.2 10.5
1 347 6.5 4.2 10.1 374 7.4 4.5 12.2
2 344 6.5 4.2 10.2 374 8.0 5.0 12.9
3 340 6.4 3.9 10.4 372 7.5 4.3 13.1
4 343 6.0 3.8 9.4 371 7.6 4.4 13.1
5 254 6.4 4.0 10.2 280 7.4 4.4 12.6
6 165 6.7 3.9 11.5 169 8.4 4.3 16.3
7 96 6.9 3.9 12.3 105 8.7 4.6 16.5
8 57 7.3 3.6 14.7 62 9.3 4.5 19.0
9 47 6.6 3.0 14.7 51 9.9 4.3 22.8
B. Secondary
cohort
0 363 9.5 5.3 17.2 352 9.1 5.1 16.2
1 361 8.9 5.0 16.1 351 9.0 5.0 16.1
2 358 9.0 4.8 16.9 348 9.7 5.2 17.8
3 354 8.9 4.7 16.8 349 10.5 5.3 20.9
4 352 9.4 4.8 18.1 346 11.7 5.4 25.4
5 351 9.0 4.4 18.6 345 12.0 5.2 27.6
6 276 9.4 4.6 19.4 262 13.8 5.4 35.4
7 186 9.5 4.6 19.5 171 16.4 6.2 43.9
8 106 9.3 4.2 20.6 103 18.4 6.3 53.5
9 91 9.5 4.2 21.9 79 18.3 6.2 54.2
patients in each treatment group showed positive rates of pro-
gression: 43% in the intensive and 45% in the conventional
groups. Approximately 10% of conventional subjects and 8% of
intensive subjects showed at least a 20% increase per year (a
fourfold increase over 8 years). However, the acute effect of
intensive treatment was to reduce the AER values at year 1 by
15% relative to those with conventional treatment. Thus, inten-
sively treated patients who developed increased AER (positive
slopes), took longer to reach defined levels of AER (such as a
value >208 j.Lglmin) than did patients in the conventional group
who had positive slopes because their AER values were 15%
lower at year 1. In the aggregate, all of these differences translated
into intensive treatment reducing the risk of reaching microalbu-
minuria and clinical albuminuria by life-table analysis.
Secondaiy intervention cohort. In contrast to the primary pre-
vention cohort, there was no difference in the acute treatment
effect between treatment groups at year 1; the ratio of geometric
means equaled 0.96 (Table 5). Thereafter values in the conven-
tionally-treated group rose on average 6.46% per year (a 65%
increase over 8 years), significantly greater than the average rate
of change among intensive subjects (—0.25% per year) for a
difference between treatment groups of 6.72% per year (P <
0.001, Table 5). Of the distribution of slopes, 47% were positive in
the intensive versus 58% in the conventional group (Fig. 6B).
Also, 13% of conventional subjects experienced at least a 30%
increase per year (an 8.2-fold increase over 8 years) versus only
3% of intensive subjects. These differences translated into inten-
sive therapy reducing the risk of reaching clinical grade albumin-
uria by 56% compared with conventional therapy by life-table
analysis (Table 2). Similar results were obtained in a separate
analysis within the Phase II secondary intervention cohort.
Table 5. Summary of regression analysis of ln(AER) over time,
adjusted for baseline ln(AER)
Estimate 95% CI. P <
A. Primary cohort
Year 1 values (Intercept)
Ratio of geometric means (I:C)
Fitted geometric means
Intensive (j.Lg/min)
Conventional (jLg/min)
Difference (I-C)
Relative (%) change (slope)
Intensive
Conventional
Difference (I-C)
0.85
6.54
7.68
—1.14
—1.31
—0.52
—0.79
(0.92, 0.79)
(6.18, 6.93)
(7.27, 8.11)
(—3.02,0.40)
(—2.16, 1.12)
(—3.16, 1.58)
0.001
0.133
0.535
0.513
Overall test for treatment group
effect (intercept and/or slope), 2df:
0.001
B. Secondary cohort
Year 1 values (intercept)
Ratio of geometric means (I:C)
Fitted geometric means
Intensive (jrg/min)
Conventional (jrg/min)
Difference (I-C)
Relative (%) change (slope)
Intensive
Conventional
Difference (I:C)
0.96
9.03
9.37
—0.33
—0.25
6.46
—6.72
(1.06, 0.88)
(8.46, 9.65)
(8.76, 10.01)
(—2.27, 1.76)
(4.40, 8.52)
(—9.60, —3.83)
0.453
0.806
0.001
0.001
Overall test for treatment group
effect (intercept and/or slope), 2df:
0.001
Feasibility cohort. A separate analysis was performed within the
feasibility phase cohort (both primary and secondary) (N = 278)
in which the majority of patients were followed for nine years.
Here the acute effect of intensive treatment was a 16% lower
mean AER at one year compared with conventional treatment.
Thereafter AER increased at a rate of 3.4%/year in the conven-
tional group compared with 1.1%/year in the intensive group (P =
0.35). The 3.4% annual increase in the conventional group is
significantly different from zero.
Analyses in subjects with AER >28 pg/mm at entry
In the secondary intervention cohort, 73 (38 treated intensively,
35 treated conventionally) subjects had AER levels >28 pg/mm,
but <139 .tg/min, at the time of entry into the study. In each
treatment group, eight developed AER >208 pg/mm at one or
more time points during the course of the study. In the intensively
treated group, AER levels had returned to normal by the end of
the study in 23 subjects, 11 maintained levels in the microalbu-
minuric range and 4 subjects developed clinical albuminuria. In
the conventionally treated subjects, AER levels had returned to
normal in 18, 11 maintained levels in the microalbuminuric range
and 6 subjects developed clinical albuminuria. These differences
in the cumulative incidence of these events were not statistically
significant, nor were differences in the distributions of the AER at
any point in time.
In these 73 subjects the difference in mean slope with intensive
versus conventional therapy, albeit not significant (P = 0.09), was
similar in magnitude (8.55%/year) to the difference in mean slope
with intensive versus conventional in those 642 secondary cohort
subjects (6.5%/yr, P < 0.0001) who entered with AER <28
pg/mm.
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Creatinine clearance
For the primary, secondary and combined cohorts, there were
no significant differences in creatinine clearance between treat-
ment groups during the study. Slope analyses using log (in)
transformed data similarly did not reveal differences between the
treatment groups in either the primary prevention or secondary
intervention cohorts (Table 6). The number of events in which
subjects experienced urinary AER >208 j.tglmin with a Cr <70
ml/min/1.73 m2 were as follows: primary prevention cohort — 0 in
the intensive and 1 in the conventional groups; secondary inter-
vention cohort — 2 in the intensive and 4 in the conventional
groups.
lothalamate clearance
lothalamate clearance was slightly but not significantly lower
during follow-up in the intensive treatment groups compared with
the conventional treatment groups (P = 0.084 in the primary
cohort and P = 0.126 in the secondary cohort) (Table 7). For
example, at year 3, the median iothalamate clearances in the
intensively and conventionally treated groups were 123 and 125
ml/min/1.73 m2, respectively, in the primary cohort and 119 and
123 ml/min/1.73 m2, respectively, in the secondary cohort. At
study end, the median iothalamate clearances in the primary
cohort were 125 and 126 ml/min/1.73 m2 in the intensively and
conventionally treated groups, respectively, and 121 in intensively
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Fig. 6. Distribution of slopes for urinaiy albumin
excretion, expressed as relative percent change per
year. The dashed line represents the distribution
of subjects on conventional therapy; the solid
0 50 100 150 200 line, those on intensive therapy. A. Primary
prevention cohort. B. Secondary intervention
cohort.
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Table 6. Summary of regression analysis of in(creatinine clearance)
over time, adjusted for baseline ln(creatinine clearance)
Estimate 95% CI. P <
A. Primary cohort
Year 1 values (intercept)
Ratio of geometric means 1.01 (1.04, 0.99)
(I:C)
Fitted geometric means
Intensive (mi/min/1.73
m2)
124.82 (122.64, 127.04)
Conventional (mi/min/ 123.45 (121.37, 125.57)
1.73 m2)
Difference (I-C) (mI/min/ 1.37
1.73 m2)
Relative (%) change (slope)
Intensive 0.27 (—0.21, 0.75) 0.272
Conventional 0.39 (—0.08, 0.85) 0.104
Difference (I-C) —0.12 (—0.78, 0.55) 0.733
Overall test for treatment group 0.669
effect (intercept and/or
slope), 2df:
B. Secondary cohort
Year 1 values (intercept)
Ratio of geometric means 1.00 (1.02, 0.97) 0.811
(I:C)
Fitted geometric means
Intensive (ml/min/1.73
m2)
122.85 (120.71, 125.02)
Conventional (mi/min/ 123.23 (121.05, 125.44)
1.73 m2)
Difference (I-C) (mi/min/
1.73 m2)
—0.38
Relative (%) change (slope)
Intensive 0.26 (—0.14, 0.66) 0.201
Conventional —0.03 (—0.45, 0.39) 0.874
Difference (I-C) 0.30 (—0.29, 0.88) 0.318
Overall test for treatment group 0.553
effect (intercept and/or
slope), 2df:
and 122 ml/min/1.73 m2 in conventionally treated groups in the
secondary cohort. In both cohorts combined, 34% of the inten-
sively treated subjects had hyperfiltration (iothalamate clearance
> 130 ml/min/1.73 m2) at year 3, compared with 39% of conven-
tionally treated subjects (P = 0.09). At year 5, 33% of intensively
treated subjects had hyperfiltration, compared with 38% of con-
ventionally treated subjects (P = 0.36),
Blood pressure/hypertension
The appearance of hypertension did not differ between treat-
ment groups in the primary, secondary or combined cohorts. In
the primary prevention cohort, 27 subjects in each treatment
group developed hypertension for a rate of 1.23 per 100 patient-
years and a 17.9% nine year cumulative incidence for the conven-
tionally treated subjects and a rate of 1.34 per 100 patient-years
and a 15.9% nine year cumulative incidence for the intensively
treated subjects. In the secondary intervention cohort, 57 conven-
tionally treated subjects developed hypertension for a rate of 2.48
per 100 patient-years and a 25.4% nine year cumulative incidence.
Fifty intensively treated subjects developed hypertension for a
rate of 2.12 per 100 patient-years and a 19.3% cumulative
incidence. (P = 0.41, compared with conventional)
Analysis of the rate of change of blood pressure showed that
Table 7. lothalamate clearance (mi/mm per 1.73 m2)
Study time Group N
25th
Quartile Median
75th
Quartile
Baseline Primary mt
Primary cony
Secondary mt
Secondary cony
148
159
64
74
114.99
113.22
117.91
116.58
122.70
126.29
129.80
124.50
135.50
138.94
144.66
140.26
3 Years Primary mt
Primary cony
Secondary mt
Secondary cony
237
264
196
218
110.22
113.89
107.02
111.07
123.28
124.67
118.77
122.76
137.03
139.96
135.78
136.77
End
(6.5 years)a
Primary mt
Primary cony
Secondary mt
Secondary cony
280
288
284
251
114.82
115.89
109.20
109.31
124.62
126.34
120.98
122.04
138.83
140.90
134.94
135.57
a Mean duration of follow-up at study end
within the primary prevention and the secondary intervention
cohorts (Table 7), there were no treatment group differences in
blood pressure at year 1. Thereafter, in both treatment groups the
mean blood pressure increased at a rate of about 0.4% per year in
the primary cohort and 0.3% per year in the secondary cohort.
These rates of increase were significant within each treatment
group, but there was no difference between treatment groups.
Because of the previously demonstrated increased incidence of
weight gain associated with intensive treatment [8], an additional
analysis was performed adjusting for both the percent of ideal
body weight at baseline and at each year during follow-up. The
results adjusting for body weight over time were comparable to
those presented in Table 8.
Analysis within subgroups
A number of subject subgroups defined by baseline variables
were examined to determine whether the beneficial effect of
intensive therapy on the development of microalbuminuria (AER
>28 .tg/min) was consistent across subgroups (Table 9). The
majority of the subject subgroups defined by age, diabetes dura-
tion, screening HbA1C, baseline smoking status, dietary protein
intake, level of retinopathy, neuropathy, the presence or absence
of hyperfiltration (Car <130 or 130 ml/min/1.73 m2) and other
variables experienced a similar beneficial effect of intensive
therapy as in the entire cohort. The beneficial effect of intensive
treatment on the risk of developing microalbuminuria (AER >28
IL/mm) was less among females (18% risk reduction) than among
males (57%; P = 0.02; data not shown). Excluding women after
the onset of pregnancy, the risk reduction was 23% (P = 0.06
compared to the risk reduction in men). Further, this difference
between the sexes was not seen when the criterion of sustained
microalbuminuria was used.
A similar analysis among subgroups was performed examining
the relative rate (%) change in AER over time (Table 10). In
general, these analyses paralleled the findings in the whole cohort.
There was a significant difference between the effect of intensive
therapy in males versus females (P = 0.03; data not shown), but
the difference did not persist if women were excluded from
analysis after the onset of pregnancy (P = 0.61).
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Table 8. Summary of regression analysis of ln(mean BP) over time,
adjusted for baseline ln(Inean BP)
Estimate 95% C.1. P <
A. Primary
Year 1 values (intercept)
Ratio of geometric means (I:C)
Fitted geometric means
Intensive (mm Hg)
Conventional (mm Hg)
Difference (I-C) (mm Hg)
Relative (%) change (slope)
Intensive
Conventional
Difference (I-C)
1.01
85.13
84.62
0.51
0.42
0.39
0.03
(1.02, 1.00)
(84.48, 85.79)
(84.00, 85.25)
(0.20, 0.63)
(0.18, 0.60)
(—0.28, 0.33)
0.277
0.001
0.001
0.867
Overall test for treatment group
effect (intercept and/or slope), 2df:
0.353
B. Secondary cohort
Year 1 values (intercept)
Ratio of geometric means (I:C)
Fitted geometric means
Intensive (mm Hg)
Conventional (mm Hg)
Difference (I-C) (mm Hg)
Relative (%) change (slope)
Intensive
Conventional
Difference (I-C)
1.00
86.87
86.76
0.12
0.26
0.35
—0.09
(1.01, 0.99)
(86.18, 87.57)
(86.05, 87.46)
(0.07, 0.46)
(0.15, 0.55)
(—0.36, 0.19)
0.811
0.009
0.001
0.544
Overall test for treatment group
effect (intercept and/or slope), 2df:
0.829
Discussion
The long-term complications of diabetes appear to develop as a
result of an interplay between the abnormal metabolic milieu of
diabetes, hemodynamic, and other as yet poorly characterized
factors. The DCCT has demonstrated a beneficial effect of
intensive diabetes treatment, resulting in a significant improve-
ment in glycemic levels, on the development and progression of
the complications of retinopathy, nephropathy and neuropathy
[8]. In this paper, we have presented a detailed analysis of the
effects of intensive therapy on renal function in the DCCT.
The number of cases developing impaired GFR by either
creatinine or iothalamate clearance was too small to permit
definitive analysis. Therefore, the development of abnormal levels
of AER served as the major outcome. Previous studies have
suggested that these may be the earliest, clinically detectable
stages of diabetic nephropathy [11—14]. Three specific levels of
AER were defined: (1) 28 g/min (40 mg/24 hr) was chosen to
represent microalbuminuria, as it is in the middle of the levels
chosen by other investigators for this purpose [11—14]; (2) 70
g/min (100 mg/24 hr) was chosen because subjects reaching
levels of 100 to 300 mg/24 hr in the Steno follow-up studies had
much greater risks of developing clinical albuminuria than did
those with levels between 30 and 99 mg/24 hours [26]; and (3)
208 .tgImin (300 mg/24 hr) was designated as clinical albumin-
uria comparable to "dipstick positive proteinuria", a recognized
stage in the evolution of diabetic nephropathy that progresses to
eventual end-stage renal disease in over 90% of affected patients
[2—6].
In both the primary prevention and secondary intervention
cohorts, intensive therapy reduced the cumulative incidence and
overall hazard rates for the development of microalbuminuria.
Intensive therapy reduced the mean adjusted relative risk by 34%
and 43% in the two cohorts, respectively, and by 39% for the
combined cohorts. Whether this reduction represents absolute
prevention or simply a delay in the onset of nephropathy cannot
be determined from this study. The numbers of subjects reaching
the higher levels of albuminuria were smaller, but again intensive
therapy reduced the risks of developing an AER >70 gImin by
51% and clinical albuminuria by 54% for the combined cohorts.
The consistent beneficial effect of intensive therapy by lifetable
and longitudinal analyses suggests that intensive therapy will at
least delay the onset and progression of nephropathy. Long-term
follow-up studies will be needed to examine whether intensive
therapy ultimately prevents the development of advanced renal
disease in IDDM patients.
The longitudinal analyses of the rates of change of AER
showed differences between the two treatment groups within
both the primary and secondary cohorts over the duration of
the trial; however, there were clearly contrasting patterns
between the two cohorts. In the primary prevention cohort,
AER was consistently higher with conventional therapy than
with intensive therapy. The principal difference was an acute
reduction of AER by 15% among intensively treated subjects in
the first year, with essentially no further change in this differ-
ence in the subsequent years of follow-up. After the first year,
the yearly percent change in AER was actually slightly negative
in both treatment groups. However, it is important to empha-
size that more than 40% of subjects in each treatment group
had positive rates of change in AER. The greater number with
positive slopes in the conventionally treated group contributed
to the greater cumulative incidence of subjects developing
microalbuminuria in this treatment group. In the secondary
cohort a different pattern emerged with an increase in AER
over time of 6.5% per year with conventional therapy versus
almost no change in the AER over time with intensive therapy.
The difference between the primary prevention and the second-
ary intervention cohorts in the rates at which AER progressed in
the conventional treatment group may reflect different stages in
the natural history of diabetic nephropathy in these separately
recruited groups of subjects with different baseline characteristics.
On the other hand, intensive therapy was effective in both cohorts,
as documented by the absence of an increase in AER over the
course of the trial. Thus at these early, but contrasting, stages in
the development of diabetic nephropathy, intensive therapy on
average prevented the development and slowed the progression of
albuminuria. Many cross sectional studies have suggested a cor-
relation between poor diabetic control and risk of development
and/or progression of diabetic nephropathy [27—37]. Smaller,
randomized studies have compared intensively treated with con-
ventionally treated patients with respect to the development of
nephropathy with conflicting results. In the Kroc Study, AER
rates fell from baseline in the intensively treated group by 8
months; however, there was no difference in the numbers of
intensive versus conventional treatment subjects progressing to
higher levels of albuminuria [38]. A similar, randomized one year
study with 12 normoalbuminuric patients in each treatment group
and achieving a similar HbA1 separation as in the DCCT showed
no significant changes in AER [39]. The two Steno studies, each of
which lasted two years, achieved difference in HbAC between
intensively and conventionally treated group of 0.5 and 1.4% and
contained 34 and 36 patients, respectively [40, 41]. Only the
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All patients
Demographic
Gender
Males
Femalesc
Age
Adolescents
Adults
IDDM
Duration
1—2.5 years
2.5—5 years
5—10 years
10—15 years
HbAlc (quartiles)
<7.83%
7.83—8.82%
8.82—10.10%
 10.10%
Clinical and biochemical features
Dietary protein (% kcal) (tertiles)
16.66%
16.66-18.99%
>18.99%
Smoking
Non-smoker
Current
History of UTI
No
Yes
Retinopathy
10/10
20/20
30/30
401<40+
Neuropathy
No
Yes
Mean blood pressure (tertiles)
<80 mm Hg
80—90 mm Hg
>90 mm Hg
AER
<10.5 g/min
10.5—28 g/min
Creatinine clearance Ccr (quartiles)
<110 ml.min/1.73m2
110—126 ml.min/1.73m2
126—143 mI.min/L73m2
>143 ml.min/1.73m2
Hyperfiltration
Ccr < 130 ml/min/1.73 m2
Ccr  130 ml.min/1.73 m2
LDL cholesterol (quartile)
<91 mg/dl
91—107 mg/dl
107—127 mg/dl
>127 mg/dl
Familial
Family history of hypertension
No
Yes
97 8.6
597 3.8
187 3.0
177 3.0
156 5.2
174 7.1
529 4.2
165 5.3
571 4.7
121 3.6
378 3.4
188 4.7
74 6.4
54 9.0
653 4.2
39 8.3
153 4.5
267 4.7
274 4.2
481 2.9
213 8.4
163 4.0
184 4.6
174 4.3
173 4.9
390 4.4
304 4.6
185 4.6
156 5.1
173 4.6
179 3.7
306 4.0
388 4.9
86 6.2
585 2.4
480 1.8
191 5.9
170 3.3
157 1.9
180 2.8
164 3.6
382 2.6
289 3.3
158 3.2
180 2.7
166 3.1
167 2.5
292 2.8
379 2.9
39 (21, 52)
57 (37, 70)
23 (—15,49)
35 (—7,60)
40 (20, 55)
28 (—20,57)
40 (—1,64)
50 (18, 69)
34 (—7,59)
15 (2, 56)
43 (13, 64)
36 (—3,60)
36 (15, 52)
48 (13, 69)
45 (27, 58)
7 (—65,48)
34 (2, 56)
48 (20, 66)
45 (18, 75)
—10 (—112,43)
37 (18, 52)
50(—15, 78)
22 (—33, 54)
54 (32, 69)
23 (—14,48)
41(15,59)
37(11,56)
22 (—29, 53)
58 (25, 76)
43 (5, 65)
33 (—6,57)
41(17, 58)
37 (105, 56)
31 (—12,57)
52(21,71)
32 (—12 58)
38 (—5, 64)
29 (—4, 52)
44 (23, 60)
Table 9. Influence of selected baseline covariates on the relative risk of microalbuminuria (AER 28 g/min) in the combined cohorts with AER
< 28 Wmin at baseline
Conventional Intensive % Reduction in riska
(95% CI.)
Heterogeneity'
P valueN Rate/100 py N Rate/100 py
694 4.5 671 2.9
376 4.6 344 2.3
318 3.8 327 2.9
238 3.3 206 2.1
199 3.3 204 2.1
134 6.6 122 4.0
123 6.2 139 4.0
168
166
178
159
7 (—63,47)
26 (—29,58)
59 (33, 75)
41(11, 62)
224 5.3 224
226 4.7 223
241 3.4 222
2.4
2.4
2.5
4.4
3.6
2.7
2.4
2.9
2.7
2.8
3.4
2.2
2.9
3.4
8.3
2.8
3.7
3.4
2.4
3.2
516
155
538
132
346
232
51
42
621
48
123
301
247
0.06
0.89
0.92
0.78
0.83
0.54
0.09
0.26
0.46
0.87
0.99
0.61
0.64
0.96
0.37
a Percentage reduction in risk of intensive compared with conventional treatment calculated from a proportional hazards regression model adjusted
for baseline AER values and stratified by primary and secondary cohorts.
bTestof equality of risk reductions among categories of the covariate obtained from a test of interaction between treatment groups and the covariate
in a proportional hazards regression model.
In order to adjust for the effects of pregnancy on AER levels women who are pregnant are censored or ignored beyond the time of pregnancy or
in the conventional group beyond the time of deviation to intensive therapy for purposes of preconception glucose control.
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Table 10. Influence of selected baseline characteristics on the treatment group effects on relative change in AER over time in the secondary cohort
N
Relative (%) change in AERJyear
Difference (I-C) P valueConventional Intensive
All patients 715 6.46 —0.25
—6.72 (—9.60, —3.83)  0.001
Gender
Male 383 8.76 0.44
—8.32 (—12.34, —4.29) 0.0001
Female 332 5.24 —1.43
—6.67 (—11.44, —1.91) 0.007
Treatment by subgroup interaction 0.606
Baseline creatinine clearance
< 130 ml/mn/1.73 m2 389 7.40 —1.36
—8.77 (—12.79, —4.74) <0.0001
 130 ml/mn/1.73 m2 326 5.37 1.09
—4.28 (—8.38, —0.17) 0.041
Treatment by subgroup interaction 0.879
Baseline IDDM duration
<5 years 145 3.13 1.84
—1.29 (—6.65, 4.07) 0.638
 5 years 570 7.42 —0.73 —8.14 (—11.49, —4.80) <0.0001
Treatment by subgroup interaction 0.540
Baseline AER
< 28 gImin 642 5.90 —0.60 —6.50 (—9.50, —3.50) <0.0001
 28 gImin 73 11.02 2.47 —8.55 (—18.34, 1.24) 0.087
Treatment by subgroup interaction 0.089
second study showed a significant effect of treatment on AER. In
the conventional treatment group, the fractional albumin clear-
ance more than doubled and 5 of the 18 patients progressed to
AER >300 mg/24 hr (208 j.Lg/min). In the intensive treatment
group, the fractional albumin clearance did not change signifi-
cantly and none of the 18 patients progressed to AER >300 mg/24
hr (208 jgImin) [41]. The change in fractional clearance in the
conventional group was significantly different from that in the
intensive group. Also, the slopes of the bimonthly AER values
over two years among patients in the conventional group were
significantly higher than those in the intensive group. A meta-
analysis of the combined studies eight (Steno 1) and five (Steno 2)
years after their completion, but according to the original treat-
ment assignment, showed that intensive treatment decreased the
number of subjects progressing to an AER level >300 mg124 hr
(208 g/min) only in patients with baseline AER levels >100
mg/24 hr [27].
In the Oslo study, patients were treated intensively with either
continuous subcutaneous insulin infusion via a pump or with
multiple insulin injections, or with conventional treatment (15 in
each of three groups) and were followed prospectively over a 43 to
47 month period. There were no significant differences in renal
outcome among the groups at study end [42]. An analysis of data
obtained from the patients when they no longer were required to
remain in their assigned treatment groups, similar to that per-
formed for the Steno studies, showed no differences in the levels
of AER in the groups when they were analyzed according to their
original "intention to treat" classification [43].
The Stockholm Diabetes Study contained the largest number of
patients (N = 102) followed for the longest period of time (5 to
7.5 years; 91 subjects completed 7.5 years) prior to the DCCT [441.
It maintained a 1.4% difference in HbA1C between treatment
groups and documented a significant treatment group effect on
the development of AER >200 g/min.
Inspection of Figures 2 through 4 helps to explain the negative
findings in some of these previous studies. It is clear that
differences between the treatment groups with respect to devel-
opment of AER levels >28 and 70 g/min did not appear until
after three years of therapy. A difference between the treatment
groups in the development of clinical albuminuria only appeared
after five years of treatment. Most of the previous studies were not
carried out long enough or with sufficient numbers of subjects to
detect treatment group differences. The beneficial effect of inten-
sive therapy in the relatively brief Steno 2 study may be explained
by the fact that the average of AER measured in two 24-hour
urine collections performed evety two months was used as the
basis for analysis. The repeated, frequent measurements may have
reduced intrapatient variability. Also, a relatively large number of
subjects entered that study with AER >70 .tg/min (but < 208
.tg/min), a point at which intensive therapy may be particularly
effective. Although the decrease in the development of clinical
albuminuria in the 73 patients who entered with AER 28 gJmin
but less than 139 tg/min was not significant in the DCCT, an
analysis of the slopes of AER over time revealed a reduction in
the mean slope with intensive versus conventional patients similar
in magnitude among these 73 patients (8.55%/year, P = 0.09) to
the difference in 642 secondary cohort patients (6.5%/year, P <
0.01) who entered with AER <28 tg/min.
The large number of patients included in the DCCT permits
examination of consistency of the beneficial effect of intensive
therapy in subgroups of patients defined by baseline characteris-
tics. These analyses show a similar reduction in risk for develop-
ment of microalbuminuria (28 j.g/min) in the intensively treated
group, irrespective of age, duration of diabetes, family history of
hypertension, smoking status, presence of neuropathy, severity of
retinopathy, and initial levels of HbAlc, blood pressure, AER,
creatinine clearance, and LDL-cholesterol.
The nearly significant difference of treatment effect in female as
contrasted with male subjects could relate to the well described
increased risk of renal disease in male patients with IDDM [45,
46]. Therefore, diabetic men may more readily benefit from an
equivalent success in achieving the goals of intensive therapy.
Stated alternatively, for a given reduction in hemoglobin Aic the
male participants may experience a greater reduction in risk for
reaching the renal benchmarks established by the DCCT and
possibly for end-stage renal disease.
In summary, intensive treatment reduced the risk of developing
any microalbuminuria by 39% and clinical albuminuria by 54%. In
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Table A. Linear trend of AER over time: Model coefficients and
variance component estimates within each cohort
Primaiy cohort Secon
Est.
dary cohort
SE P<Est. SE P<
Coefficients
Intercept (yr 1) 1.305 0.055 <0.001 1.008 0.065 0.001
a1: Group (I = —1, —0.080 0.020 <0.001 —0.018 0.024 0.46C = + 1)
13o: Time (yr) —0.0092 0.006 0.13 0.031 0.007 0.001
f3: Group X Time —0.0040 0.006 0.52 —0.034 0.007 0.001
6: Baseline 0.346 0.027 <0.001 0.543 0.027 0.001
(In Wmin)
Variance components
o: Intercept (a) 0.138 0.016 <0.001 0.259 0.022 0.001
o: Time (13)
af3
o: Within subjects
0.0075 0.0013
0.0011 0.0036
0.303 0.0080
<0.001
0.77
<0.001
0.024
0.0066
0.319
0.0020
0.0049
0.0077
0.001
0.18
0.001
subjects in the secondary intervention cohort, with longer dura-
tion and higher baseline AER levels, the rate of increase in AER
in the intensive treatment group was virtually zero compared with
6.5%/year with conventional therapy. Whether these changes
represent only a retardation of development and progression or
represent prevention of diabetic nephropathy in a subset of
patients can only be determined by a prolonged follow-up of these
patients. These data, coupled with the benefits also shown for
diabetic retinopathy and neuropathy, outweigh the risk of severe
adverse effects with intensive treatment. [8] They constitute strong
support for the institution of intensive therapy in most patients
with IDDM unless there are specific factors that would alter this
benefit:risk ratio.
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Appendix
Random effects longitudinal models of albumin excretion rate
Regression models
Longitudinal growth-curve analyses [23, 241 were performed separately
within each treatment group, and for both groups combined. Separate
analyses were performed using only a linear trend over time, and then
using both a linear and a quadratic trend. Analyses were performed using
the program 5V of BMDP [261 and the estimates obtained using maximum
likelihood [24] are presented. In all cases, analyses using REML [23] yield
nearly identical results.
The linear trend statistical models employed in these analyses are of the
following form. The intensive and conventional treatment groups are
designated as j' = I or C, respectively, and i refers to an individual subject
in either group. Then let X refer to the natural log (In) of the baseline
measure obtained prior to randomization, and Y,, refer to the ln of the
followup measure at time t, (t = 1 9) for the i-th patient in the j-th
group.
Table 1I.a. The secondary cohort: Quadratic model of AER over time:
Coefficients and variance component estimates
Est. SE P<
Coefficients
a. Intercept (year 1) 0.976 0.065 0.001
a1: Group (I = —1, C = + 1) —0.015 0.026 0.56
13: Linear trend in time (years) 0.072 0.015 0.001
Group )< linear trend —0.036 0.015 0.019
o: Quadratic trend (yr)2 —0.0065 0.0021 0.002
6: Group X quadratic trend 0.0002 0.0021 0.92
v: Baseline (In mg/24 hr) 0.540 0.027 0.001
Variance components
o: Intercept (a) 0.253 0.025 0.001
o: Time linear (f3)
a: Time quadratic (6)
0.00040
0.00055
0.0015
0.00014
0.80
0.001
o: Within subjects 0.3035 0.0078 0.001
Table B.b. The secondary cohort: Summary of quadratic trend
regression analysis of AER over time
Estimate 95% CI. P<
Year 1 Values (intercept)
Ratio of geometric means (I:C) 0.97 (1.07, 0.88) 0.556
Fitted geometric means 8.72 (8.12, 9.35)
Intensive (g/min)
Conventional (g/min) 8.98 (8.36, 9.65)
Difference (I-C) (j.g/min) —0.27
Relative (%) change (slope)
Intensive 3.66 (—0.52, 7.83) 0.086
Conventional 10.80 (6.55, 15.05) 0.001
Difference (I-C) —7.14 (—13.10, —1.19) 0.019
Derivative of relative (%) change
Intensive —0.63 (—1.20, —0.05) 0.033
Conventional —0.67 (—1.26, —0.08) 0.033
Difference (I-C) 0.04 (—0.78, 0.86) 0.920
Overall test for treatment group 0.001
effect (intercept and/or slope),
3df:
Separate group-specific models. Within each group separately (j = I or
C), the group specific linear trend model is of the following form:
= + j33(t — 1) + + (1)
where the errors, 51j1. are assumed to be independently normally distrib-
uted with mean zero and variance o. This model has two structural
components. For the i-th subject (in the j-th group) this model states that
the expected value of the In (measure) at any time t, E(Y,,), is a linear
function of the baseline value X with slope y, for the members of the j-th
group. This provides an "adjustment" for the baseline value. The model
also states that E(Y11) is a linear function of time for each subject through
a subject-specific intercept a1 and slope 1l for the i-th subject in the j-th
group.
Within the j-th group, however, the as and f3s themselves are also
assumed to be jointly normally distributed with a mean intercept n and a
mean slope /3 for all the subjects in that group. Since time enters the
model as (t — 1), then the average intercept reflects the acute effect of
that treatment on the levels at year 1, and the average slope j3 reflects the
long-term trend in that group beyond the first year. A test of the difference
between these average group intercepts ( vs. is a test of a difference
in the acute (short-term) effects of treatment. Likewise, a test of the
difference between these average slopes (I3 vs. P) is a test of a difference
in the long-term effects of treatment.
Another feature of these models is that within each group, the
subject-specific intercepts and slopes are randomly distributed with vari-
ances and o, respectively, and covariance These variance
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Table C.a. Linear trend model of AER over time: Coefficients and variance component estimates within the primary cohort
Intensive Conventional I vs. C
Est. SE P< Est. SE P< P<
Coefficients
a: Intercept (yr 1) 1.215 0.069 <0.001 1.392 0.083 <0.001 0.16
/3: Time (yr) —0.012 0.0081 0.15 —0.0059 0.0088 0.51 0.62
v: Baseline (in mg/24 h) 0.350 0.034 <0.001 0.343 0.040 <0.001 0.90
Variance components
o: Intercept (a) 0.768 0.0173 <0.001 0.1939 0.0264 <0.001
o: Time (/3) 0.0055 0.0015 <0.001 0.0091 0.0020 <0.001
<0.001
0.15
Of3: a/3 0.0050 0.0042 0.23 —0.0020 0.0058 0.74
o: Within subjects 0.2868 0.0109 <0.001 0.3190 0.0117 <0.001
0.33
0.05
Table C.b. Linear trend model of AER over time: Coefficients and variance component estimates within the secondary cohort
Intensive Conventional I vs. C
Est. SE P< Est. SE P< P<
a: Intercept (yr 1) 0.952 0.090 <0.001 1.067 0.092 <0.001 0.39
/3: Time (yr) —0.0019 0.0081 0.82 0.063 0.012 <0.001 <0.001
v: Baseline (in mg/24 h) 0.559 0.037 <0.001 0.525 0.039 <0.001 0.53
Variance components
o: Intercept (a) 0.2779 0.0312 <0.001 0.2410 0.0310 <0.001
Time (/3) 0.0115 0.0017 <0.001 0.0371 0.0040 <0.001
0.41
<0.001
17: a/3 0.0045 0.0055 0.41 0.0087 0.0080 0.28
o: Within subjects 0.2960 0.0100 <0.001 0.3441 0.0119 <0.001
0.67
0.002
components reflect the degree of variation of the intercepts and slopes
within the j-th group. Within a treatment group, the method of maximum
likelihood provides estimates of the coefficients , p, and , and of the
variance components a, o, o. and o, and also provides estimates of
the large-sample standard errors of each. This allows tests of the signifi-
cance of differences between groups.
A single model with treatment group effects. Another, more general
approach is to assume that the variance components are equal in the two
treatment groups and to then fit a single model which incorporates
treatment group effects in the coefficients. Here we let i designate a subject
from both treatment groups combined. For the i-th subject, an additional
variable G is used to designate the treatment group of that subject, where
G = +1 if I, or —1 if C. The overall model then is of the form
Y1t = a10 + aG -4- f3jo(t — 1) + 131G(t — 1) + yX1 + jt (2)
As before, the intercepts a10 and slopes /3 are assumed to be randomly
distributed in the population with means and 13o, and variance
components o, o, and covariance o; and the errors Cit are indepen-
dently distributed with mean zero and variance o. Because the UI = 1,
then the mean intercept and slopes in the two groups are expressed as:
Intercept Slope
a1=0+a1 I3=o+Pi
Conventional: ac = o — a1 /3 = o — 13i (3)
Thus, a test that a1 = 0 is equivalent to a test that = and a test
that /3 = 0 is equivalent to a test that J3 = J3. Each of these hypotheses
can be tested using a 1 df standard normal (or chi square) Wald test based
on the estimated coefficients and their standard errors. In addition, an
overall test of treatment group difference in either the intercepts and/or
the slopes (a test that both a1 and f3 equal zero) is provided by a 2 df Wald
chi square test obtained as a contrast among the estimates and their
covariance matrix.
Albumin excretion rate
Linear trend models. Appendix Table A presents the fit of the model (2)
to the ln(AER) measures separately within the primary and the secondary
cohorts. This model was used as the basis for Table 4. Because the
dependent variable is the ln(AER), then e2 is the ratio of the geometric
means of intensive to conventional treatment (I:C), and a test that a1 is
zero is equivalent to a test that this ratio is one. Confidence limits on the
ratio can be obtained by likewise transforming the confidence limits on a1.
Under the model (2), the geometric mean AER in each group at year 1,
where t = 1 and (t — 1) = 0, are obtained as
e1G+
where G = +1 if I, or —1 if C; and where X is the overall mean of the
baseline ln(AER). The exponent is the mean of the ln(AER) under the
model and its standard error can be obtained from the variance of the
linear combination of the parameter estimates. This then provides confi-
dence limits on the mean of the ln(AER). Transforming these confidence
limits yields asymmetric confidence limits on these geometric means. The
difference between the estimated geometric means is also presented in
Table 4.
To describe the long-term trend over time, the coefficient /3 in the above
models represents the change in the mean of Y per unit change in t, that
is, per year. Since Y represents the ln(AER), then e reflects the relative
change over time, and (e'3 — 1) * 100 is the percent change per year. For
values of /3 relatively close to zero, this expression is approximately equal
to simply /3 * 100. Thus, the coefficient itself can be interpreted (approx-
imately) as the relative change in AER (sg/min) per year. In the model
(2), the slopes in each group are obtained from (3), and the variance of the
estimated slopes is obtained from the variance of the respective linear
combinations of the estimates of f3 and /3, and likewise that for the
difference between groups. A test that is zero then is a test of no
treatment group differences in long-term trend.
Overall, the groups may differ either in their intercepts (a1) or in their
slopes (/3k): An overall test of treatment group effect, therefore, is
obtained as a 2 dl test that both of these coefficients equal zero versus the
alternative that either or both are different from zero. The p-value for this
test is presented in Table 4.
Quadratic trend models. Separately within the primary and the second-
ary cohorts, quadratic trend analyses were also performed in which
quadratic time effect terms b10(t — 1)2 and b11G(t — 1)2 were added to
model (2), with a corresponding mean and variance component, b10 and
a, respectively, for the random effect. Quadratic effects were only
significant in the model for the secondary cohort; this model is presented
Intensive:
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in Appendix Table B. Table B.a presents the fitted model coefficients and
variance components, and Table B.b presents the model in terms of the
rate of change over time. In this model, the quadratic effect corresponds
to the effect of the square of time on the ln(AER), thus describing the
second derivative of the curve relating AER to time. Thus, the quadratic
effect can be interpreted as the derivative of the relative percent change in
AER per year, or as the rate of change in the slope over time.
As in Table A, there is a significant linear trend and a significant
treatment group difference in this trend. In addition, there was a signifi-
cant overall quadratic trend (b10) but the group by quadratic trend
interaction (b,) was not significant, indicating no significant difference
between groups (Table B.a). The respective derivatives of the percent
change per year are presented in Table B.b. In each group, these
derivatives are negative and are nominally significant (P < 0.035 for each).
Since a positive linear trend in the ln(AER) represents a convex trend in
AER, then a negative quadratic trend will dampen the rate of increase in
AER within both treatment groups. Thus, in the intensive group, for
example, the percent change during the second year (t = 2) is 3.66 —
(0.63)(2 — 1) = 3.03% change from the value at year ito that at year 2.
Linear trend components of variance. Appendix Table C presents the fit
of the group-specific linear trend models (1) separately for the intensive
and conventional treatment groups within the primary cohort (Table C.a)
and the secondary cohort (Table C.b). Also presented are tests of
differences between groups for the various model parameters using a large
sample Z-test (two-sided). Within the primary cohort, the only additional
finding compared to Appendix Table A is that the variance component for
the intercepts (o) differs significantly between groups, the variance
among conventional group patients being threefold greater than that
among intensive group patients. Thus, a greater fraction of conventional
than intensive group patients had a "high" intercept. Also the error
variance (o) was significantly higher (at P < 0.05) among conventional
than intensive group patients, indication a better fit of the model among
the latter.
Within the secondary cohort (Table C.b), the trend coefficients are
significantly different, as was the case in Table 3. Also, the variance of the
slopes (o) is threefold greater among conventional than intensive group
patients (P < 0.001). Thus, the distribution of slopes among conventional
subjects not only has a greater mean, but also a greater variance (spread)
than that of intensive subjects. This indicates that a higher fraction of
conventional subjects showed a progression in AER.
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